{"protocolSection":{"identificationModule":{"nctId":"NCT01620489","orgStudyIdInfo":{"id":"NN2211-3916"},"secondaryIdInfos":[{"id":"2011-002968-24","type":"EUDRACT_NUMBER"},{"id":"U1111-1122-3303","type":"OTHER","domain":"WHO"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment","officialTitle":"Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial"},"statusModule":{"statusVerifiedDate":"2019-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-06-14","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2013-08-20","type":"ACTUAL"},"completionDateStruct":{"date":"2013-08-20","type":"ACTUAL"},"studyFirstSubmitDate":"2012-06-13","studyFirstSubmitQcDate":"2012-06-13","studyFirstPostDateStruct":{"date":"2012-06-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-08-20","resultsFirstSubmitQcDate":"2014-10-23","resultsFirstPostDateStruct":{"date":"2014-10-30","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-03-06","lastUpdatePostDateStruct":{"date":"2019-03-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment.\n\nThe trial medication will be add-on to the subject's stable pre-trial OAD and/or insulin regimen."},"conditionsModule":{"conditions":["Diabetes","Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":279,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Lira 1.8 mg","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"type":"DRUG","name":"liraglutide","description":"1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.","armGroupLabels":["Lira 1.8 mg"]},{"type":"DRUG","name":"placebo","description":"Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)","description":"Calculated as the estimated mean change from baseline in HbA1c (%) after 26 Weeks of treatment based on the statistical model.","timeFrame":"Week 0, Week 26"}],"secondaryOutcomes":[{"measure":"Estimated Proportion of Responders Achieving HbA1c <7.0% and no Weight Gain After 26 Weeks of Treatment","description":"Calculated as estimated percentage of subjects achieving HbA1c \\<7.0% and no weight gain after 26 weeks of treatment based on the statistical model.","timeFrame":"At week 26"},{"measure":"Estimated Proportion of Responders Achieving HbA1c <7.0% and no Minor or Severe Hypoglycaemic Episodes After 26 Weeks of Treatment","description":"Calculated as estimated percentage of subjects achieving HbA1c \\<7.0% and no minor or severe hypoglycaemic episodes observed within 26 weeks of treatment based on the statistical model.","timeFrame":"At week 26"},{"measure":"Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Self-measured Plasma Glucose (SMPG) 7-point Profiles","description":"SMPG was measured before and 90 minutes after breakfast, lunch and dinner and at bedtime at Week 0, 12 and 26. A summary measure of the 7 values was derived for each applicable visit as the area under the curve divided by the period of time elapsed between the first and last measurement. The change from baseline to week 26 was estimated using the statistical model.","timeFrame":"Week 0, week 26"},{"measure":"Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Body Mass Index (BMI)","description":"Calculated as estimated mean change in BMI (kg/m˄2) from baseline to Week 26 based on the statistical model.","timeFrame":"Week 0, week 26"},{"measure":"Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula)","description":"Calculated as the estimated ratio to baseline in eGFR (mL/min/1.73m˄2) after 26 Weeks of treatment based on the statistical model.","timeFrame":"Week 0, week 26"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects diagnosed with type 2 diabetes with stable diabetes treatment (unchanged medication and unchanged dose) for 90 days prior to the screening visit including: Monotherapy or any duo-combinations of metformin and/or SUs and/or pioglitazone. Metformin should be used with caution in subjects with moderate renal failure and must be used in accordance with local metformin labelling or guidelines. Or Monotherapy or any combinations of metformin and/or pioglitazone and/or basal or premix insulin. Insulin adjustments (total daily dose) below or equal to 10% within 90 days prior to the screening visit as confirmed by the investigator are acceptable. Metformin should be used with caution in subjects with moderate renal failure and must be used in accordance with local metformin labelling or guidelines. Combination of pioglitazone and insulin should be used with caution and according to local labelling or guidelines\n* HbA1c 7-10% (both inclusive)\n* Moderate renal impairment diagnosed more than 90 days prior to the screening visit and confirmed by an eGFR (glomerular filtration rate) of 30-59 mL/min/1.73 m2 per MDRD (modification of diet in renal disease) formula at the screening visit\n* Body Mass Index (BMI) 20-45 kg/m\\^2 (both inclusive)\n\nExclusion Criteria:\n\n* Recurrent severe hypoglycaemia or hypoglycaemic unawareness as judged by the investigator\n* Treatment with antidiabetic medication(s) other than stated in the inclusion criteria in a period of 90 days prior to screening. Previous short-term (below or equal to 7 days in total) treatment with rapid-or short-acting insulin in connection with intercurrent illness is allowed at the discretion of the investigator\n* Impaired liver function, defined as ALAT (alanine aminotransferase) above or equal to 2.5 times upper normal limit\n* History of chronic pancreatitis or idiopathic acute pancreatitis\n* Within the past 180 days any of the following: Episode of unstable angina, acute coronary event, cerebral stroke/transient ischemic attack (TIA) or other significant cardiovascular event (including e.g. arrhythmias or conduction delays on ECG (electrocardiogram))\n* Heart failure defined as New York Heart Association (NYHA) class IV\n* A systolic blood pressure above or equal to 180 mmHg or a diastolic blood pressure above or equal to 100 mmHg\n* Rapidly progressing renal disease (e.g., acute glomerulonephritis) at the discretion of the investigator\n* Use of immunosuppressive treatment within 90 days prior to screening\n* Diagnosis or treatment for cancer in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)\n* Proliferative retinopathy or maculopathy requiring acute treatment as judged by the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Global Clinical Registry (GCR, 1452)","affiliation":"Novo Nordisk A/S","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Novo Nordisk Investigational Site","city":"Concord","state":"California","zip":"94520","country":"United States","geoPoint":{"lat":37.97798,"lon":-122.03107}},{"facility":"Novo Nordisk Investigational Site","city":"La Jolla","state":"California","zip":"92037","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Novo Nordisk Investigational Site","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Novo Nordisk Investigational Site","city":"Monterey","state":"California","zip":"93940","country":"United States","geoPoint":{"lat":36.60024,"lon":-121.89468}},{"facility":"Novo Nordisk Investigational Site","city":"San Diego","state":"California","zip":"92111","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Novo Nordisk Investigational Site","city":"San Ramon","state":"California","zip":"94583","country":"United States","geoPoint":{"lat":37.77993,"lon":-121.97802}},{"facility":"Novo Nordisk Investigational Site","city":"Torrance","state":"California","zip":"90502","country":"United States","geoPoint":{"lat":33.83585,"lon":-118.34063}},{"facility":"Novo Nordisk Investigational Site","city":"Tustin","state":"California","zip":"92780","country":"United States","geoPoint":{"lat":33.74585,"lon":-117.82617}},{"facility":"Novo Nordisk Investigational Site","city":"Ventura","state":"California","zip":"93003","country":"United States","geoPoint":{"lat":34.27834,"lon":-119.29317}},{"facility":"Novo Nordisk Investigational Site","city":"Golden","state":"Colorado","zip":"80401","country":"United States","geoPoint":{"lat":39.75554,"lon":-105.2211}},{"facility":"Novo Nordisk Investigational Site","city":"Boynton Beach","state":"Florida","zip":"33472","country":"United States","geoPoint":{"lat":26.52535,"lon":-80.06643}},{"facility":"Novo Nordisk Investigational Site","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Novo Nordisk Investigational Site","city":"Miami","state":"Florida","zip":"33156","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Novo Nordisk Investigational Site","city":"Pembroke Pines","state":"Florida","zip":"33027","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"Novo Nordisk Investigational Site","city":"Plantation","state":"Florida","zip":"33324","country":"United States","geoPoint":{"lat":26.13421,"lon":-80.23184}},{"facility":"Novo Nordisk Investigational Site","city":"St. Petersburg","state":"Florida","zip":"33711","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"Novo Nordisk Investigational Site","city":"Atlanta","state":"Georgia","zip":"30303","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Novo Nordisk Investigational Site","city":"Roswell","state":"Georgia","zip":"30076","country":"United States","geoPoint":{"lat":34.02316,"lon":-84.36159}},{"facility":"Novo Nordisk Investigational Site","city":"Avon","state":"Indiana","zip":"46123","country":"United States","geoPoint":{"lat":39.76282,"lon":-86.39972}},{"facility":"Novo Nordisk Investigational Site","city":"Franklin","state":"Indiana","zip":"46131","country":"United States","geoPoint":{"lat":39.48061,"lon":-86.05499}},{"facility":"Novo Nordisk Investigational Site","city":"Greenfield","state":"Indiana","zip":"46140","country":"United States","geoPoint":{"lat":39.78504,"lon":-85.76942}},{"facility":"Novo Nordisk Investigational Site","city":"Muncie","state":"Indiana","zip":"47304","country":"United States","geoPoint":{"lat":40.19338,"lon":-85.38636}},{"facility":"Novo Nordisk Investigational Site","city":"Slidell","state":"Louisiana","zip":"70461-4231","country":"United States","geoPoint":{"lat":30.27519,"lon":-89.78117}},{"facility":"Novo Nordisk Investigational Site","city":"Rockville","state":"Maryland","zip":"20852","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Novo Nordisk Investigational Site","city":"Springfield","state":"Massachusetts","zip":"01199","country":"United States","geoPoint":{"lat":42.10148,"lon":-72.58981}},{"facility":"Novo Nordisk Investigational Site","city":"Buckley","state":"Michigan","zip":"49620","country":"United States","geoPoint":{"lat":44.50445,"lon":-85.67701}},{"facility":"Novo Nordisk Investigational Site","city":"Southfield","state":"Michigan","zip":"48034-7661","country":"United States","geoPoint":{"lat":42.47337,"lon":-83.22187}},{"facility":"Novo Nordisk Investigational Site","city":"Great Falls","state":"Montana","zip":"59405","country":"United States","geoPoint":{"lat":47.50024,"lon":-111.30081}},{"facility":"Novo Nordisk Investigational Site","city":"Nashua","state":"New Hampshire","zip":"03063","country":"United States","geoPoint":{"lat":42.76537,"lon":-71.46757}},{"facility":"Novo Nordisk Investigational Site","city":"Rosedale","state":"New York","zip":"11422","country":"United States","geoPoint":{"lat":40.66205,"lon":-73.73541}},{"facility":"Novo Nordisk Investigational Site","city":"Staten Island","state":"New York","zip":"10301","country":"United States","geoPoint":{"lat":40.56233,"lon":-74.13986}},{"facility":"Novo Nordisk Investigational Site","city":"Greenville","state":"North Carolina","zip":"27834","country":"United States","geoPoint":{"lat":35.61266,"lon":-77.36635}},{"facility":"Novo Nordisk Investigational Site","city":"Mooresville","state":"North Carolina","zip":"28117","country":"United States","geoPoint":{"lat":35.58486,"lon":-80.81007}},{"facility":"Novo Nordisk Investigational Site","city":"Franklin","state":"Ohio","zip":"45005","country":"United States","geoPoint":{"lat":39.55895,"lon":-84.30411}},{"facility":"Novo Nordisk Investigational Site","city":"Mason","state":"Ohio","zip":"45040-6815","country":"United States","geoPoint":{"lat":39.36006,"lon":-84.30994}},{"facility":"Novo Nordisk Investigational Site","city":"Wadsworth","state":"Ohio","zip":"44281-9236","country":"United States","geoPoint":{"lat":41.02561,"lon":-81.72985}},{"facility":"Novo Nordisk Investigational Site","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Novo Nordisk Investigational Site","city":"McMurray","state":"Pennsylvania","zip":"15317","country":"United States","geoPoint":{"lat":40.27785,"lon":-80.08394}},{"facility":"Novo Nordisk Investigational Site","city":"Norristown","state":"Pennsylvania","zip":"19401","country":"United States","geoPoint":{"lat":40.1215,"lon":-75.3399}},{"facility":"Novo Nordisk Investigational Site","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Novo Nordisk Investigational Site","city":"East Providence","state":"Rhode Island","zip":"02914","country":"United States","geoPoint":{"lat":41.81371,"lon":-71.37005}},{"facility":"Novo Nordisk Investigational Site","city":"Chattanooga","state":"Tennessee","zip":"37404-1192","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Novo Nordisk Investigational Site","city":"Chattanooga","state":"Tennessee","zip":"37411","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Novo Nordisk Investigational Site","city":"Kingsport","state":"Tennessee","zip":"37660","country":"United States","geoPoint":{"lat":36.54843,"lon":-82.56182}},{"facility":"Novo Nordisk Investigational Site","city":"Amarillo","state":"Texas","zip":"79106","country":"United States","geoPoint":{"lat":35.222,"lon":-101.8313}},{"facility":"Novo Nordisk Investigational Site","city":"Lubbock","state":"Texas","zip":"79423","country":"United States","geoPoint":{"lat":33.57786,"lon":-101.85517}},{"facility":"Novo Nordisk Investigational Site","city":"Sugar Land","state":"Texas","zip":"77479","country":"United States","geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"Novo Nordisk Investigational Site","city":"Newport News","state":"Virginia","zip":"23606","country":"United States","geoPoint":{"lat":36.98038,"lon":-76.42975}},{"facility":"Novo Nordisk Investigational Site","city":"Richmond","state":"Virginia","zip":"23219","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Novo Nordisk Investigational Site","city":"Richmond","state":"Virginia","zip":"23294","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Novo Nordisk Investigational Site","city":"Richmond","state":"Virginia","zip":"23298","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Novo Nordisk Investigational Site","city":"Winchester","state":"Virginia","zip":"22601","country":"United States","geoPoint":{"lat":39.18566,"lon":-78.16333}},{"facility":"Novo Nordisk Investigational Site","city":"Milwaukee","state":"Wisconsin","zip":"53209","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"Novo Nordisk Investigational Site","city":"Brest","zip":"29609","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"facility":"Novo Nordisk Investigational Site","city":"La Roche-sur-Yon","zip":"85295","country":"France","geoPoint":{"lat":46.66974,"lon":-1.42757}},{"facility":"Novo Nordisk Investigational Site","city":"La Rochelle","zip":"17019","country":"France","geoPoint":{"lat":46.16308,"lon":-1.15222}},{"facility":"Novo Nordisk Investigational Site","city":"Pointe à Pitre","zip":"97159","country":"France","geoPoint":{"lat":44.07984,"lon":1.98937}},{"facility":"Novo Nordisk Investigational Site","city":"Strasbourg","zip":"67000","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Novo Nordisk Investigational Site","city":"Bialystok","zip":"15-381","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"Novo Nordisk Investigational Site","city":"Bialystok","zip":"15-435","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"Novo Nordisk Investigational Site","city":"Gdansk","zip":"80-546","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Novo Nordisk Investigational Site","city":"Katowice","zip":"40-767","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"Novo Nordisk Investigational Site","city":"Krakow","zip":"31-261","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Novo Nordisk Investigational Site","city":"Poznan","zip":"60-111","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Novo Nordisk Investigational Site","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Novo Nordisk Investigational Site","city":"Zabrze","zip":"41-800","country":"Poland","geoPoint":{"lat":50.32492,"lon":18.78576}},{"facility":"Novo Nordisk Investigational Site","city":"Barnaul","zip":"656045","country":"Russia","geoPoint":{"lat":53.36199,"lon":83.72786}},{"facility":"Novo Nordisk Investigational Site","city":"Kazan'","zip":"420043","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"Novo Nordisk Investigational Site","city":"Kursk","zip":"305035","country":"Russia","geoPoint":{"lat":51.72689,"lon":36.18457}},{"facility":"Novo Nordisk Investigational Site","city":"Moscow","zip":"117036","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Novo Nordisk Investigational Site","city":"Moscow","zip":"123448","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Novo Nordisk Investigational Site","city":"Moscow","zip":"127411","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Novo Nordisk Investigational Site","city":"Nizhny Novgorod","zip":"603126","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"Novo Nordisk Investigational Site","city":"Penza","zip":"440026","country":"Russia","geoPoint":{"lat":53.19568,"lon":45.01075}},{"facility":"Novo Nordisk Investigational Site","city":"Saint Petersburg","zip":"194358","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Novo Nordisk Investigational Site","city":"Saint Petersburg","zip":"195257","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Novo Nordisk Investigational Site","city":"Saint Petersburg","zip":"199034","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Novo Nordisk Investigational Site","city":"Samara","zip":"443067","country":"Russia","geoPoint":{"lat":53.20767,"lon":50.13553}},{"facility":"Novo Nordisk Investigational Site","city":"Saratov","zip":"410031","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"Novo Nordisk Investigational Site","city":"Saratov","zip":"410039","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"Novo Nordisk Investigational Site","city":"Saratov","zip":"410053","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"Novo Nordisk Investigational Site","city":"Smolensk","zip":"214019","country":"Russia","geoPoint":{"lat":54.77826,"lon":32.05088}},{"facility":"Novo Nordisk Investigational Site","city":"Volgograd","zip":"400138","country":"Russia","geoPoint":{"lat":48.71378,"lon":44.4976}},{"facility":"Novo Nordisk Investigational Site","city":"Kharkiv","zip":"61000","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Novo Nordisk Investigational Site","city":"Kiev","zip":"04053","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Novo Nordisk Investigational Site","city":"Kyiv","zip":"04114","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Novo Nordisk Investigational Site","city":"Vinnytsia","zip":"21010","country":"Ukraine","geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"Novo Nordisk Investigational Site","city":"Zaporizhia","zip":"69600","country":"Ukraine"},{"facility":"Novo Nordisk Investigational Site","city":"Bristol","zip":"BS10 5NB","country":"United Kingdom","geoPoint":{"lat":51.45523,"lon":-2.59665}},{"facility":"Novo Nordisk Investigational Site","city":"Dundee","zip":"DD1 9SY","country":"United Kingdom","geoPoint":{"lat":56.46913,"lon":-2.97489}},{"facility":"Novo Nordisk Investigational Site","city":"Edinburgh","zip":"EH4 2XU","country":"United Kingdom","geoPoint":{"lat":55.95206,"lon":-3.19648}},{"facility":"Novo Nordisk Investigational Site","city":"Hull","zip":"HU3 2RW","country":"United Kingdom","geoPoint":{"lat":53.7446,"lon":-0.33525}},{"facility":"Novo Nordisk Investigational Site","city":"Leicester","zip":"LE5 4PW","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"facility":"Novo Nordisk Investigational Site","city":"Letchworth Garden City","zip":"SG6 4UB","country":"United Kingdom","geoPoint":{"lat":51.97938,"lon":-0.22664}},{"facility":"Novo Nordisk Investigational Site","city":"London","zip":"E1 2EF","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Novo Nordisk Investigational Site","city":"London","zip":"SE5 9RT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Novo Nordisk Investigational Site","city":"Swansea","zip":"SA6 6NL","country":"United Kingdom","geoPoint":{"lat":51.62079,"lon":-3.94323}}]},"referencesModule":{"references":[{"pmid":"26681713","type":"RESULT","citation":"Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, Bosch-Traberg H, Syren A, Umpierrez GE. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care. 2016 Feb;39(2):222-30. doi: 10.2337/dc14-2883. Epub 2015 Dec 17."},{"pmid":"30663196","type":"RESULT","citation":"Zobel EH, von Scholten BJ, Goldman B, Persson F, Hansen TW, Rossing P. Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. Diabetes Obes Metab. 2019 May;21(5):1261-1265. doi: 10.1111/dom.13638. Epub 2019 Feb 22."},{"pmid":"39963952","type":"DERIVED","citation":"Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2."},{"pmid":"29729957","type":"DERIVED","citation":"Kim JD, Park CY, Cha BY, Ahn KJ, Kim IJ, Park KS, Lee HW, Min KW, Won JC, Chung MY, Kim JT, Kang JG, Park SW. Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes. Clin Ther. 2018 May;40(5):752-761.e2. doi: 10.1016/j.clinthera.2018.04.002. Epub 2018 May 3."}],"seeAlsoLinks":[{"label":"Clinical Trials at Novo Nordisk","url":"http://novonordisk-trials.com"}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"This trial was conducted in France, Poland, Russian Federation, Ukraine, United Kingdom, and the United States of America.","groups":[{"id":"FG000","title":"Lira 1.8 mg","description":"Subjects received subcutaneous (s.c) liraglutide 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."},{"id":"FG001","title":"Placebo","description":"Subjects received s.c placebo 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial OAD and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"140"},{"groupId":"FG001","numSubjects":"139"}]},{"type":"Exposed","achievements":[{"groupId":"FG000","numSubjects":"140"},{"groupId":"FG001","comment":"2 subjects did not take trial product","numSubjects":"137"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"105"},{"groupId":"FG001","comment":"2 subjects did not take trial product","numSubjects":"105"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"34"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Withdrawal Criteria","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"25"}]},{"type":"Unclassified","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Lira 1.8 mg","description":"Subjects received subcutaneous (s.c) liraglutide 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."},{"id":"BG001","title":"Placebo","description":"Subjects received s.c placebo 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial OAD and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"137"},{"groupId":"BG002","value":"277"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.0","spread":"8.3"},{"groupId":"BG001","value":"66.3","spread":"8.0"},{"groupId":"BG002","value":"67.2","spread":"8.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"137"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"140"}]}]}]},{"title":"Fasting plasma glucose (FPG)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"mmol/L","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9.48","spread":"3.270"},{"groupId":"BG001","value":"9.27","spread":"2.842"},{"groupId":"BG002","value":"9.38","spread":"3.061"}]}]}]},{"title":"Glycosylated haemoglobin (%)(HbA1c)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Percent (%) glycosylated haemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.08","spread":"0.792"},{"groupId":"BG001","value":"8.00","spread":"0.853"},{"groupId":"BG002","value":"8.04","spread":"0.823"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)","description":"Calculated as the estimated mean change from baseline in HbA1c (%) after 26 Weeks of treatment based on the statistical model.","populationDescription":"The full analysis set (FAS) included all randomised subjects that received at least one dose of the study medication. A total of 14 subjects in the FAS did not contribute to the analysis due to missing data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage (%)","timeFrame":"Week 0, Week 26","groups":[{"id":"OG000","title":"Lira 1.8 mg","description":"Subjects received subcutaneous (s.c) liraglutide 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."},{"id":"OG001","title":"Placebo","description":"Subjects received s.c placebo 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial OAD and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.05","spread":"0.8944"},{"groupId":"OG001","value":"-0.38","spread":"0.8797"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis of no treatment difference was tested using a two-sided test based on a mixed model repeated measurement (MMRM) analysis. The model included treatment, country, stratification groups (6 groups from cross-classifying renal function category (2 levels: eGFR\\<45 and ≥45 mL/min) and the background insulin treatment category (3 levels: basal, premix or no insulin)) as fixed effects factors and baseline HbA1c as a covariate, all nested within week.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"Adjustment for multiple comparisons was not used since there was only one primary endpoint.","statisticalMethod":"Mixed Models Analysis","paramType":"Estimated treatment difference","paramValue":"-0.66","ciPctValue":"95","ciLowerLimit":"-0.90","ciUpperLimit":"-0.43"}]},{"type":"SECONDARY","title":"Estimated Proportion of Responders Achieving HbA1c <7.0% and no Weight Gain After 26 Weeks of Treatment","description":"Calculated as estimated percentage of subjects achieving HbA1c \\<7.0% and no weight gain after 26 weeks of treatment based on the statistical model.","populationDescription":"The FAS included all randomised subjects that received at least one dose of study medication. A total of 14 subjects in the FAS did not contribute to the analysis due to missing data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of patients","timeFrame":"At week 26","groups":[{"id":"OG000","title":"Lira 1.8 mg","description":"Subjects received subcutaneous (s.c) liraglutide 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."},{"id":"OG001","title":"Placebo","description":"Subjects received s.c placebo 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial OAD and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.03"},{"groupId":"OG001","value":"15.99"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysed by a logistic regression model with treatment, country and stratification groups as fixed effects and HbA1c and body weight at baseline as covariates. No weight gain was defined as change from baseline to Week 26 in body weight ≤0 kg.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"Not adjusted for multiple comparisons","statisticalMethod":"Regression, Logistic","paramType":"Estimated odds ratio","paramValue":"4.48","ciPctValue":"95","ciLowerLimit":"2.46","ciUpperLimit":"8.18"}]},{"type":"SECONDARY","title":"Estimated Proportion of Responders Achieving HbA1c <7.0% and no Minor or Severe Hypoglycaemic Episodes After 26 Weeks of Treatment","description":"Calculated as estimated percentage of subjects achieving HbA1c \\<7.0% and no minor or severe hypoglycaemic episodes observed within 26 weeks of treatment based on the statistical model.","populationDescription":"The FAS included all randomised subjects that received at least one dose of study medication. A total of 14 subjects in the FAS did not contribute to the analysis due to missing data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of patients","timeFrame":"At week 26","groups":[{"id":"OG000","title":"Lira 1.8 mg","description":"Subjects received subcutaneous (s.c) liraglutide 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."},{"id":"OG001","title":"Placebo","description":"Subjects received s.c placebo 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial OAD and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.23"},{"groupId":"OG001","value":"11.23"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysed by a logistic regression model with treatment, country and stratification groups as fixed effects and HbA1c at baseline as covariates.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"Not adjusted for multiple comparisons","statisticalMethod":"Regression, Logistic","paramType":"Estimated odds ratio","paramValue":"3.94","ciPctValue":"95","ciLowerLimit":"2.12","ciUpperLimit":"7.30"}]},{"type":"SECONDARY","title":"Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Self-measured Plasma Glucose (SMPG) 7-point Profiles","description":"SMPG was measured before and 90 minutes after breakfast, lunch and dinner and at bedtime at Week 0, 12 and 26. A summary measure of the 7 values was derived for each applicable visit as the area under the curve divided by the period of time elapsed between the first and last measurement. The change from baseline to week 26 was estimated using the statistical model.","populationDescription":"The FAS included all randomised subjects that received at least one dose of study medication. A total of 46 subjects in the FAS did not contribute to the analysis due to missing data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 26","groups":[{"id":"OG000","title":"Lira 1.8 mg","description":"Subjects received subcutaneous (s.c) liraglutide 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."},{"id":"OG001","title":"Placebo","description":"Subjects received s.c placebo 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial OAD and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"122"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":"2.480"},{"groupId":"OG001","value":"-0.51","spread":"2.391"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Mean change from baseline in the 7-point profile (SMPG) after 26 weeks treatment was analysed using an MMRM model with treatment, country and stratification groups as fixed effects and baseline as a covariate, all nested within visit.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"Not adjusted for multiple comparisons","statisticalMethod":"Mixed Models Analysis","paramType":"Estimated treatment difference","paramValue":"-1.08","ciPctValue":"95","ciLowerLimit":"-1.58","ciUpperLimit":"-0.58"}]},{"type":"SECONDARY","title":"Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Body Mass Index (BMI)","description":"Calculated as estimated mean change in BMI (kg/m˄2) from baseline to Week 26 based on the statistical model.","populationDescription":"The FAS included all randomised subjects that received at least one dose of study medication. A total of 14 subjects in the FAS did not contribute to the analysis due to missing data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kg/m^2","timeFrame":"Week 0, week 26","groups":[{"id":"OG000","title":"Lira 1.8 mg","description":"Subjects received subcutaneous (s.c) liraglutide 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."},{"id":"OG001","title":"Placebo","description":"Subjects received s.c placebo 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial OAD and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"1.3214"},{"groupId":"OG001","value":"-0.38","spread":"1.1679"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Change from baseline in BMI (kg/m˄2) after 26 weeks treatment was analysed separately using an MMRM analysis model with treatment, country and stratification groups as fixed effects and baseline as a covariate, all nested within visit.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"= 0.0022","statisticalMethod":"Mixed Models Analysis","statisticalComment":"Not adjusted for multiple comparisons","paramType":"Estimated treatment difference","paramValue":"-0.51","ciPctValue":"95","ciLowerLimit":"-0.83","ciUpperLimit":"-0.18"}]},{"type":"SECONDARY","title":"Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula)","description":"Calculated as the estimated ratio to baseline in eGFR (mL/min/1.73m˄2) after 26 Weeks of treatment based on the statistical model.","populationDescription":"Safety analysis set included all subjects receiving at least one dose of the trial product. A total of 8 subjects in the safety analysis set did not contribute to the analysis due to missing data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"mL/min/1.73m˄2","timeFrame":"Week 0, week 26","groups":[{"id":"OG000","title":"Lira 1.8 mg","description":"Subjects received subcutaneous (s.c) liraglutide 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."},{"id":"OG001","title":"Placebo","description":"Subjects received s.c placebo 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial OAD and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"0.17"},{"groupId":"OG001","value":"1.01","spread":"0.19"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The ratio to baseline in eGFR (mL/min/1.73m˄2) after 26 weeks treatment was estimated based on log-transformed data for changes from baseline. The responses were analysed using an MMRM model with treatment, country and stratification groups as fixed effects and log-transformed baseline as a covariate, all nested within visit. The resulting estimates were back-transformed to the original scale.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"= 0.3575","pValueComment":"Not adjusted for multiple comparisons","statisticalMethod":"Mixed Models Analysis","paramType":"Estimated treatment ratio","paramValue":"0.98","ciPctValue":"95","ciLowerLimit":"0.94","ciUpperLimit":"1.02"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"The adverse events were collected from Week 0 to Week 27±3 Days","description":"Safety analysis set included all subjects receiving at least one dose of the investigational product.","eventGroups":[{"id":"EG000","title":"Lira 1.8 mg","description":"Subjects received subcutaneous (s.c) liraglutide 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone).","seriousNumAffected":14,"seriousNumAtRisk":140,"otherNumAffected":73,"otherNumAtRisk":140},{"id":"EG001","title":"Placebo","description":"Subjects received s.c placebo 1.8 mg once daily, applying a 3-4 week dose escalation regimen with weekly increments of 0.6 mg until the maintenance dose of 1.8 mg was reached, as an add-on to the subject's stable pre-trial OAD and/or insulin regimen (monotherapy or any duo-combinations of metformin and/or sulphonylureas and/or pioglitazone; or monotherapy of basal or premix insulin or combination with metformin and/or pioglitazone).","seriousNumAffected":15,"seriousNumAtRisk":137,"otherNumAffected":49,"otherNumAtRisk":137}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Autoimmune hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Arteriosclerotic gangrene","organSystem":"Infections and infestations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Biliary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Meningitis herpes","organSystem":"Infections and infestations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Spinal cord injury lumbar","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Glomerular filtration rate decreased","organSystem":"Investigations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Urine albumin/creatinine ratio increased","organSystem":"Investigations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Benign neoplasm of cervix uteri","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Endometrial adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Urethral stenosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":140},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Colectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Arteriosclerosis","organSystem":"Vascular disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Poor peripheral circulation","organSystem":"Vascular disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":140},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]}],"otherEvents":[{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":140},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":137}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":140},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":137}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":30,"numAtRisk":140},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":137}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":140},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":137}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":140},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":137}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":140},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":137}]},{"term":"Glomerular filtration rate decreased","organSystem":"Investigations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":140},{"groupId":"EG001","numEvents":14,"numAffected":7,"numAtRisk":137}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":21,"numAtRisk":140},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":137}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":140},{"groupId":"EG001","numEvents":8,"numAffected":4,"numAtRisk":137}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"Version 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":140},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":137}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication."},"pointOfContact":{"title":"Public Access to Clinical Trials","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069450","term":"Liraglutide"}],"ancestors":[{"id":"D052216","term":"Glucagon-Like Peptide 1"},{"id":"D004763","term":"Glucagon-Like Peptides"},{"id":"D052336","term":"Proglucagon"},{"id":"D005768","term":"Gastrointestinal Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"}]}},"hasResults":true}